Skip to content

An MRI-guided Treatment Strategy to Prevent Disease Progression in Patients With Rheumatoid Arthritis

Does an MRI-guided Treatment Strategy Reduce Disease Activity and Progression in Patients With Rheumatoid Arthritis (RA): a Randomised Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01656278
Acronym
IMAGINE-RA
Enrollment
200
Registered
2012-08-02
Start date
2012-03-31
Completion date
2017-05-31
Last updated
2017-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases, Connective Tissue Diseases, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases

Keywords

Arthritis, Rheumatoid/drug therapy, Arthritis, Rheumatoid/pathology, Disease Progression, Longitudinal Studies, Prospective Studies, Imaging, Magnetic Resonance, Remission Induction, Synovitis/immunology, Synovitis/pathology, Wrist Joint/pathology, Wrist Joint/physiopathology

Brief summary

The purpose of this study is to examine whether an magnetic resonance imaging (MRI) -guided treatment strategy based on a predefined treatment algorithm can prevent progression of erosive joint damage, increase remission rate and improve functional level in the short and long term in patients with rheumatoid arthritis (RA).

Detailed description

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease. Patients typically experience pain, functional impairment and reduced quality of life, and are at risk of developing progressive joint damage. The disease primarily affects the small joints of the hands and feet. The current treatment strategy involves early and intensive treatment with close clinical follow up, which attempts to control the disease and avoid inflammation and thereby prevent pain, improve functional level and avoid joint damage. It is therefore important for optimal treatment of RA patients that methods used for diagnosis, disease monitoring and prognostication are highly sensitive. Erosive joint damage occurs early in the disease. Joint deformity is irreversible and causes serious functional impairment. Early and intensive treatment with close monitoring of the inflammation can slow the destructive disease and prevent function loss. However, it has been demonstrated that patients who are shown by conventional clinical and biochemical examination to have low disease activity or to be in remission can still have progressive joint damage. This demonstrates that current clinical/biochemical methods used in daily clinical practice are not sufficiently sensitive and other methods are required for the monitoring of disease activity and prognostication. The presence of erosions (shown by X-ray examination) as well as anti-cyclic citrullinated peptide (anti-CCP) antibodies and bone marrow oedema (osteitis) on magnetic resonance imaging (MRI), are all independent predictors of subsequent radiographic progression. Bone marrow oedema has been shown to be the strongest independent predictor in early RA and MRI therefore has significant prognostic value. It is therefore possible that supplementing conventional clinical and biochemical examinations of RA patients with MRI, and intensifying treatment where bone marrow oedema is present, will help reduce disease activity, avoid progressive joint damage and prevent function loss. The current study is therefore based on the following hypothesis: By supplementing conventional clinical and biochemical examination of RA patients with low disease activity/in remission with MRI and intensifying treatment in the case of sub-clinical inflammation as measured by the presence of bone marrow oedema, it is possible to prevent radiographic erosive progression, improve functional level and enable more patients to achieve clinical remission.

Interventions

PROCEDUREMagnetic resonance imaging (MRI)

Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one physically swollen joint and DAS28\>3.2 AND/OR MRI-detected bone marrow oedema score \> 0 (RAMRIS-score)

OTHERConventional biochemical and clinical examinations

Treatment algorithm based on conventional biochemical and clinical examinations. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one clinically swollen joint and DAS28\>3.2

Sponsors

King Christian X´Hospital for Rheumatic Diseases
CollaboratorOTHER
Slagelse Hospital
CollaboratorOTHER
Glostrup University Hospital, Copenhagen
CollaboratorOTHER
Abbott
CollaboratorINDUSTRY
Professor of Rheumatology, MD, DMSci, Kim Horslev-Petersen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years * RA according to ACR (American College of Rheumatology)/EULAR (European League Against Rheumatism) 2010 criteria. * Anti-CCP positivity * Erosions on conventional X-ray of hands, wrists and/or feet * No clinically swollen joints * DAS28 (4 variable, CRP) \< 3.2 * DMARD monotherapy treatment OR combination treatment, in the form of 2- or 3-drug therapy. If the patient is undergoing 3-drug therapy, at least one of the preparations must be administered at less than the maximum inclusion dose\* * Unchanged anti-rheumatic treatment in the previous 6 weeks or more * No previous treatment with biological medication * No contra-indications for TNF-alpha-inhibiting treatment * No contra-indications for MRI * s-creatinine within normal range * Ability and willingness to give written and oral informed consent and fulfil the requirements of the study programme with reference to the protocol * Maximum inclusion dose is defined as: MTX 25 mg/week (or maximum tolerated dose if 25 mg/week is not tolerated), SSZ 2g/day (or maximum tolerated dose if 2 g/day is not tolerated) and HCQ 200 mg/day (or maximum tolerated dose if 200 mg/day is not tolerated)

Exclusion criteria

* Previous or current biological treatment * Known intolerance to methotrexate treatment which means that the patient is not able to tolerate a minimum of MTX 7.5 mg (minimum dose). * DMARD 3-drug therapy at maximum tolerated/maximum inclusion dose\* * I.m, intra-articular or i.v glucocorticoid administration ≤ 6 weeks prior to inclusion * Oral glucocorticoid administration \> 5 mg/day * Changes in oral glucocorticoid dose \< 3 months prior to inclusion * Myocrisin treatment * Affected liver enzymes \> 2 x the upper limit of normal at the time of screening * Current and/or imminent wish to become pregnant * Contra-indications for TNF-alpha-inhibiting treatment * Contra-indications for MRI * Known alcohol/drug abuse * Inability to give informed consent * Inability to cooperate with the study programme due to physical or mental reasons

Design outcomes

Primary

MeasureTime frame
No radiographic progression (assessed by the Sharp/vdHeijde method).24 month
DAS28 remission (<2.6)24 month

Secondary

MeasureTime frameDescription
No MRI erosion (RAMRIS) score24 monthNo progression in MRI erosion (RAMRIS) score from 0-12 and 12-24 months and change in MRI erosion (RAMRIS) score from 0-12, 0-24 and 12-24 months.
MRI synovitis (RAMRIS) score24 monthsMRI synovitis (RAMRIS) score at 12 and 24 months
MRI bone marrow oedema (RAMRIS) score24 monthsMRI bone marrow oedema (RAMRIS) score at 12 and 24 months
HAQ score24 monthChanges in HAQ score from 0-12 and 0-24 months
SF-36 score24 monthChanges in SF-36 score from 0-12 and 0-24 months
ACR/EULAR 2011 remission24 monthACR/EULAR 2011 remission at 12 and 24 months
DAS2824 monthDAS28 at 12 and 24 month
DAS28 remission (<2.6) at 12 months24 months
biomarker analyses24 month
EQ-5D score24 monthChanges in EQ-5D score from 0-12 and 0-24 months
No radiographic progression (Sharp/vdHeijde score).24 monthNo radiographic progression (Sharp/vdHeijde score) from 0-12 and 12-24 months and change in Sharp/vdHeijde score from 0-12, 0-24 and 12-24 months.

Other

MeasureTime frameDescription
Dynamic MRI24 monthDynamic MRI variable (including initial rate of enhancement (IRE) and maximum enhancement (ME)).

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026